Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of alzheimers disease
State Availability
The STEP trials (Semaglutide Treatment Effect in People with obesity) tested weekly semaglutide at 2.4 mg (a higher dose than for diabetes) in people with obesity (BMI 30 or 27+comorbidity)
Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach
The multiple-target drug had better effects, while the single-target drugs showed a significant improvement in steatosis and glucose metabolism, particularly with GLP-1RAs
US$ 27.73
US$ 29.20
US$ 27.86
US$ 27.36
US$ 26.50
